Two Novartis Phase III Studies Show Twice as Many Ph+ CML Patients Achieve Deeper Levels of Response With Tasigna® Compared to Gleevec®

Two Novartis Phase III Studies Show Twice as Many Ph+ CML Patients Achieve Deeper Levels of Response With Tasigna® Compared to Gleevec®

Dec 12, 2011
Source URL: https://qa1.novartis.us/us-en/news/media-releases/two-novartis-phase-iii-studies-show-twice-many-ph-cml-patients-achieve-deeper-levels-response-tasigna-compared-gleevec-0

List of links present in page
  1. https://qa1.novartis.us/us-en/us-en/news/media-releases/two-novartis-phase-iii-studies-show-twice-many-ph-cml-patients-achieve-deeper-levels-response-tasigna-compared-gleevec-0